Imara sells PDE9 program (tovinontrine) to Cardurion for $34.75M upfront plus milestones

Enliven Therapeutics, Inc.

Imara to receive $34.75M upfront at closing for tovinontrine and all PDE9 assets; plus $250k previously paid.
Potential milestone payments: $10M for proof-of-concept/clinical milestones, $50M for regulatory/commercial milestones.
Transaction requires stockholder approval; Board unanimously approved; termination fee of $1.5M.
Retention agreements amended for CEO Rahul Ballal and CFO/COO Michael Gray, with 50% payable on definitive agreement and 50% on closing.
Company will continue evaluating strategic alternatives post-sale, including possible liquidation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.